Department of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
J Immunol Res. 2018 Jun 28;2018:1943497. doi: 10.1155/2018/1943497. eCollection 2018.
Obesity, one of the most severe public health problems of the 21st century, is a common metabolic syndrome due to excess body fat. The incidence and severity of obesity-related asthma have undergone a dramatic increase. Because obesity-related asthma is poorly controlled using conventional therapies, alternative and complementary therapies are urgently needed. Lipid metabolism may be abnormal in obesity-related asthma, and immune modulation therapies need to be investigated. Herein, we describe the immune regulators of lipid metabolism in obesity as well as the interplay of obesity and asthma. These lay the foundations for targeted therapies in terms of direct and indirect immune regulators of lipid metabolism, which ultimately help provide effective control of obesity-related asthma with a feasible treatment strategy.
肥胖症是 21 世纪最严重的公共卫生问题之一,是一种由于体脂肪过多而导致的常见代谢综合征。肥胖相关性哮喘的发病率和严重程度呈显著增加趋势。由于常规疗法对肥胖相关性哮喘的控制效果不佳,因此迫切需要替代和补充疗法。肥胖相关性哮喘的脂代谢可能异常,需要对免疫调节疗法进行研究。本文描述了肥胖症中脂质代谢的免疫调节剂,以及肥胖症与哮喘之间的相互作用。这些为脂质代谢的直接和间接免疫调节剂的靶向治疗奠定了基础,最终有助于提供有效的肥胖相关性哮喘控制的可行治疗策略。